D
Medicus Pharma Ltd. MDCX.V
TSX
Recommendation
Prev Close
$5.69
Volume
--
Avg Vol (90D)
0
Market Cap
$39.55M
Dividend & Yield
--
52-Week Range
$2.55 - $7.60
P/E (TTM)
--
EPS (TTM)
-$1.78
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Medicus Pharma advances D-MNA with FDA engagement, strong Phase 2 progress, and solid balance sheet
8/25/2025 - Proactive Investors - UK
Medicus Pharma (NASDAQ:MDCX) versus Pluri (NASDAQ:PLUR) Head to Head Review
8/23/2025 - Zolmax
Medicus Pharma (MDCX) Maintains 'Buy' Rating with $27 Target MDCX Stock News
8/22/2025 - GuruFocus
How The Pieces Add Up: IWC Targets $191
8/22/2025 - ETF Channel
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) ...
8/21/2025 - GuruFocus
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
8/21/2025 - Newsfile Corp. - News Releases
Medicus Pharma and HelixNano sign MOU to co-develop thermostable, needle-free mRNA vaccines
8/5/2025 - Proactive Investors - UK
Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines
8/4/2025 - Proactive Investors - UK
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies ...
8/4/2025 - GuruFocus
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
8/4/2025 - Newsfile Corp. - News Releases
Private Advisor Group LLC Takes Position in Medicus Pharma Ltd (NASDAQ:MDCX)
8/3/2025 - Ticker Report
Medicus Pharma Appoints Deloitte for Licensing Deal
7/30/2025 - TipRanks Financial Blog
Medicus Pharma shareholders approve new board members and FDA submission for Skin Cancer therapy
7/23/2025 - Proactive Investors - UK
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of ...
7/23/2025 - GuruFocus
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
7/23/2025 - Newsfile Corp. - News Releases
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 MDCX Stock News
7/21/2025 - GuruFocus
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
7/21/2025 - Newsfile Corp. - News Releases
Medicus Pharma Enters Warrant Inducement Agreement
7/14/2025 - TipRanks Financial Blog
Medicus Pharma (MDCX) Rating and Price Target Overview MDCX Stock News
7/9/2025 - GuruFocus
Market movers: Amazon, Freeport-McMoRan, SharpLink, HIVE, Medicus Pharma...
7/8/2025 - Proactive Investors - UK
Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment
7/8/2025 - Proactive Investors - UK
Medicus Pharma Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment
7/8/2025 - TipRanks Financial Blog
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug ...
7/8/2025 - GuruFocus
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
7/8/2025 - Newsfile Corp. - News Releases
Medicus Pharma expands pipeline with Antev acquisition - ICYMI
7/5/2025 - Proactive Investors - UK
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$5.30M
EBIT (TTM)
-$16.50M
Net Income (TTM)
-$16.51M
Balance Sheet
Total Assets (Q)
$11.93M
Total Debt (Q)
$5.09M
Total Liabilities (Q)
$8.69M
Book Value Per Share (Q)
$0.2039
Cash Flow
Cash from Operations (TTM)
-$15.75M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$17.01M
Net Change in Cash (TTM)
$1.26M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 17 and 21 (est)
Price History
Loading...
Beta
--
7-Day Total Return
0.00%
30-Day Total Return
0.00%
60-Day Total Return
0.00%
90-Day Total Return
0.00%
Year to Date Total Return
44.05%
1-Year Total Return
29.91%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Nov 21, 2024 - $2.55
52-week High
Oct 07, 2024 - $7.60
Valuation
Market Cap
$39.55M - Nano Cap
Enterprise Value
$34.97M
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
14.28
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
medicuspharma.com
Phone Number
Address
One First Canadian Place
100 King Street West - Suite 3400
Toronto, ON M5X 1A4
Country
Canada
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets. It is developing SKNJCT-003, which is in Phase 2 study for the... more